Literature DB >> 9217189

IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade.

P A Rowlings1, D Przepiorka, J P Klein, R P Gale, J R Passweg, P J Henslee-Downey, J Y Cahn, S Calderwood, A Gratwohl, G Socié, M M Abecasis, K A Sobocinski, M J Zhang, M M Horowitz.   

Abstract

Acute graft-versus-host disease (GVHD) severity is graded by pattern of organ involvement and clinical performance status using a system introduced by Glucksberg and colleagues 21 years ago. We examined how well Glucksberg grade predicted transplant outcome and constructed a Severity Index not requiring subjective assessment of performance in 2881 adults receiving an HLA-identical sibling T-cell-depleted (n = 752) or non-T-cell-depleted (n = 2129) bone marrow transplant for leukaemia between 1986 and 1992. Relative risks (RR) of relapse, treatment-related mortality (TRM) and treatment failure (TF) (relapse or death) were calculated for patients with (Glucksberg Grade I, II or III/IV acute (GVHD) versus those without acute GVHD and for patients with distinct patterns of organ involvement regardless of Glucksberg grade. Using data for non-T-cell-depleted transplants, a Severity Index was developed grouping patients with patterns of organ involvement associated with similar risks of TRM and TF. Higher Glucksberg grade predicted poorer outcome; however, patients with the same grade but different patterns of skin, liver or gut involvement often had significantly different outcomes. The revised Severity Index groups patients in four categories, A-D. Compared to patients without acute GVHD, RRs (95% confidence interval) of TF were 0.85 (0.69, 1.05) for patients with Index A, 1.21 (1.02, 1.43) with B, 2.19 (1.78, 2.71) with C, and 5.69 (4.57, 7.08) with D. Prognostic utility of the Index was tested in patients receiving T-cell-depleted transplants; similar RRs of TF were observed. An acute GVHD Severity Index is proposed to enhance design and interpretation of clinical trials in the current era of allogeneic blood and bone marrow transplantation.

Entities:  

Mesh:

Year:  1997        PMID: 9217189     DOI: 10.1046/j.1365-2141.1997.1112925.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  217 in total

Review 1.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

3.  Low-dose antithymocyte globulin for treatment of steroid-pulse-resistant acute graft-versus-host disease.

Authors:  Kazuteru Ohashi; Yuji Tanaka; Shin-ichiro Mori; Yoshiki Okuyama; Kiyoshi Hiruma; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

4.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

5.  Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Authors:  Esperanza B Papadopoulos; Miguel-Angel Perales; Jenna D Goldberg; Joanne F Chou; Steven Horwitz; Julie Teruya-Feldstein; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Sergio Giralt; Ann A Jakubowski; Guenther Koehne; Marcel R M van den Brink; James W Young; Zhigang Zhang
Journal:  Leuk Lymphoma       Date:  2012-01-31

6.  Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.

Authors:  Eneida R Nemecek; Ralf A Hilger; Alexia Adams; Bronwen E Shaw; Deidre Kiefer; Jennifer Le-Rademacher; John E Levine; Gregory Yanik; Wing Leung; Julie-An Talano; Paul Haut; David Delgado; Neena Kapoor; Aleksandra Petrovic; Roberta Adams; Rabi Hanna; Hemalatha Rangarajan; Jignesh Dalal; Joseph Chewning; Michael R Verneris; Stacy Epstein; Lauri Burroughs; Evelio D Perez-Albuerne; Michael A Pulsipher; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

7.  A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.

Authors:  Craig S Sauter; Joanne F Chou; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; James W Young; Michael Scordo; Sergio Giralt; Hugo Castro-Malaspina
Journal:  Leuk Lymphoma       Date:  2014-03-20

8.  Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.

Authors:  Yeon Joo Lee; Dick Chung; Kun Xiao; Esperanza B Papadopoulos; Juliet N Barker; Trudy N Small; Sergio A Giralt; Junting Zheng; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-22       Impact factor: 5.742

9.  Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival.

Authors:  Amro Mohamed Sedky El-Ghammaz; Rima Ben Matoug; Maha Elzimaity; Nevine Mostafa
Journal:  Support Care Cancer       Date:  2017-04-24       Impact factor: 3.603

Review 10.  GVHD: biology matters.

Authors:  James L M Ferrara; Mohammed S Chaudhry
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.